The onychomycosis treatment market size was valued at USD 3.76 billion in 2024 and is expected to reach USD 5.40 billion by 2032, growing at a CAGR of 4.67% over the forecast period of 2025-2032.
The global onychomycosis treatment market is exhibiting significant growth due to an increase in the prevalence of fungal nail infections, an increasing geriatric population, and the increased awareness of personal hygiene and nail health. The rise in demand for minimally invasive treatment options, together with the proven track record of topical and oral antifungal therapies are additional factor propelling the growth of this market. Increasing numbers of regulatory approvals for a new product and better access to dermatologicals are also likely to propel the growth of the onychomycosis market trends during the forecast period in developing regions.
The U.S. onychomycosis treatment market size was valued at USD 1.14 billion in 2024 and is expected to reach USD 1.60 billion by 2032, growing at a CAGR of 4.37% over the forecast period of 2025-2032. North America accounts for the largest share of the onychomycosis treatment market, due to a strong healthcare infrastructure, a high level of patient awareness, and a high volume of prescriptions in the U.S. The deep dermatological care and the availability of topical and oral antifungal therapies always make it a dominant market player in the region.
Drivers:
Increase in Onychomycosis and Fungal Infections Drives Market Growth
The Onychomycosis treatment market analysis is primarily driven by the surging global prevalence of onychomycosis. The elderly, the diabetic, the immunosuppressed, and those who have been in wet environments, such as swimmers and athletes, are particularly susceptible to this condition. The increasing prevalence of chronic diseases combined with hot, humid temperature also facilitate. Its early stages are often undiagnosed, and, as the disease progresses and becomes more difficult to manage, there continues to be an increasing need for effective therapeutic options. The growing population of patients has a direct role in propelling the demand for prescription and OTC antifungal therapy options.
Globally, onychomycosis affects approximately 4–10% of adults, 20% over the age of 60, and 50% over the age of 70, according to MDPI.
Others with comorbidities, diabetes, immunosuppression, and hemodialysis patients have rates as high as 19%–52%, highlighting an ever-expanding patient denominator.
Market Growth Driven by Innovations in Topical and Oral Antifungal Treatments
Improvements in efficacy and availability of topically and orally delivered antifungal agents have facilitated improved design and analyses of therapeutic options. A new generation of topical formulation protocols with greater nail penetration and enhanced adhesion properties, enabling the active ingredient to penetrate deeper in a more effective manner. As an example, they now have lacquers and medicated creams it has been designed for extended wear and high absorption. The oral side, drugs are more available, terbinafine variants carry greater bioavailability and lower potential toxicity, which increases their attractiveness to prescribers and patients. The innovations, which contribute to improved treatment outcomes and compliance, have further fueled the onychomycosis treatment market growth.
This recent randomized trial of a new topical antifungal nail solution achieved a mycological cure in 55% of patients treated versus only 2.6% of those on placebo.
Restraints:
Long Treatment Duration and Poor Patient Compliance are Halting the Market Growth
The prolonged time taken to cure the condition is one of the major issues in the onychomycosis treatment market trends. Patients may have to apply the medication daily for 6 to 12 months, and even longer for toenail infections, where the nail grows more slowly. Oral antifungals, although initially faster-acting, also necessitate weeks to months of continuous therapy.
Such long-term treatment inevitably contributes to poor adherence as patients stop treatment when symptoms disappear or due to inconvenience. Not all people complete the entire course of the drug, which is important for the complete removal of the fungus. Incomplete treatment can promote recurrence and development of drug resistance, leading to reduced efficacy of therapy and reduced trust in available options, both treatments and clinicians. This continues to constrain the overall growth of the market, with low adherence rates.
By Type
Distal subungual onychomycosis segment dominated the market with a 42.60% in 2024, as it is the most prevalent form, occurring in patients of all ages, but is most common in older adults and individuals with diabetes or suppressed immune systems. Distal subungual onychomycosis, which starts at the nail bed and works its way upward, is the most recognized form of the nail infection. Chronicity, resistance to self-care, and progressive course increase the need for a medical solution, frequently with prescription oral antifungal agents and sustained management, and contribute to strong market leadership.
The white deep onychomycosis segment is expected to grow at the fastest rate during the forecast period due to its growing stage identification, increasing aesthetic awareness, and growing availability of effective topical therapies. This is a unique type of onychomycosis as it only involves the more superficial parts of the nail plate and is highly responsive to topical therapy if treated early. Driven by consumers and providers who want high-velocity, cosmetic-based cures, the effective topical treatments used for this form of infection are designed for rapid acquisition by businesses, driving fast-paced growth.
By Treatment
In 2024, onychomycosis treatment market was dominated by the topical segment, which is attributed to the easy availability and ease of administering onychomycosis treatment topically and increasing preference of patients for non-invasive treatment options. Topical antifungal agents are commonly the first line of therapy in mild to moderate cases, due to limited systemic side effects and availability without prescription in many countries. Topical formulations, such as lacquers or medicated creams with enhanced nail penetration have improved efficacy and adherence in comparison to earlier preparations.
The oral treatment segment is anticipated to experience the fastest growth over the forecast period as it is more effective in treating moderate to severe or recurrent onychomycosis cases. Although topical antifungals are effective in some cases, oral antifungals such as terbinafine and itraconazole yield quicker and more consistent results by circulating in the bloodstream to get to the infection, especially in the case of deep involvement of the nail bed. Oral therapies are more favorable amongst healthcare providers due to the increasing incidence of more resistant fungal infections associated with an increasing global burden of chronic conditions, such as diabetes and immunodeficiency.
By End Use
The dermatology clinics segment dominated the onychomycosis treatment market share with a 52.04% in 2024, driven by oriented treatment along with the desire for specialized and targeted treatment. Fungal nail infections are targeted at dermatology clinics, which can provide specialized treatments, such as advanced topical therapies, laser treatment, and cosmetic nail apparatus, which are not available in primary health care facilities. These clinics have an average of shorter waiting times for appointments, which helps to individualize treatment, and follow-up for chronic diseases such as onychomycosis.
The hospitals segment is anticipated to have the highest growth over the forecast period, as they are well equipped to cater to patients with moderate to severe, recurrent, or complicated onychomycosis. This typically includes hospitalization with diagnostic testing, systemic oral antifungal therapy, and addressing comorbidities, such as diabetes and vascular disease. The rising tide of chronic diseases around the globe is placing an ever-growing demand for hospital-based intervention in many cases where topical treatment has failed.
North America dominated the onychomycosis treatment market with a 41.03% market share in 2024 due to the presence of a well-established healthcare infrastructure and high patient awareness, along with easy access to dermatological services in the region. Fungal nail infections are highly prevalent in the region, especially in the elderly and diabetics. Moreover, increasing penetration of key pharma companies, regular approvals of advanced topical and oral antifungal drugs, and insurance for treatment will drive the market positively. This dominance is mainly incited by the U.S., where the prescription of medication is high, along with a proactive approach in diagnosing and treating patients.
Hallux Subungual Gel (terbinafine injection) is a Novel drug delivery under Phase II in the US, suggesting a trend toward locally injected therapies and other minimally invasive therapies.
Asia Pacific represents the fastest-growing region in the onychomycosis treatment market with 5.46% CAGR as a result of increasing awareness regarding nail health, improving access to healthcare, and a rising geriatric population. The market players in countries, such as China, India, and Japan are witnessing a high demand for both over-the-counter and prescription antifungal treatments, propelled by rising per capita income and urbanization. Additionally, health systems are improving quickly, and consumers are also shifting towards hygiene and aesthetic care. The growth of advanced treatment options in this region is further aided by government initiatives and distribution networks.
Europe is a lucrative market due to the well-established healthcare system, increasing awareness about fungal nail infections, and the preference of patients for treatment that doesn’t involve invasive procedures. These factors are gradually boosting the target patient pool receiving treatment in the region due to the increasing elderly population and rising incidence of diabetes. Also, better dermatologic access and the development of topically acting antifungal medicines have enhanced the availability of early diagnostic and therapeutic measures.
Germany, France, the U.K., and Italy lead the market expansion mainly due to the strong R&D and presence large scale of large-scale pharmaceutical companies. Enhanced adoption has also resulted from favorable reimbursement policies as well as the ease of purchase of over-the-counter antifungal products. Moreover, increasing concern related to hygiene, aesthetic appeal, and general health is supporting the need for efficient onychomycosis treatment in the European region.
Latin America is demonstrating steady growth over the forecast period due to the rising awareness about fungal infections and slow progress in healthcare access. Onychomycosis is becoming more common in this country owing to the warm and humid climate of the region, along with high prevalence of diabetes and other immunocompromised states. An increase in access to public health campaigns and dermatological services has led to many patients presenting for early diagnosis and treatment.
The MEA region is exhibiting significant growth as a result of urbanization, heightened disposable incomes, and improved healthcare infrastructure in a number of nations. Awareness around personal hygiene, along with the aesthetic nature of the fungal nail infection, has increased the need for treatment, especially in developed markets, such as the UAE and Saudi Arabia.
Key Players:
The major onychomycosis treatment market companies are Bausch Health Companies, Pfizer, Novartis, Bayer, GlaxoSmithKline, Johnson & Johnson, Cipla, Moberg Pharma, Teva Pharmaceutical Industries, Galderma, and other players.
February 2024 – Vanda Pharmaceuticals Inc., a global biopharmaceutical industry leader, reported that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) request to test VTR-297 for the treatment of onychomycosis. This is an important development in the progression of new antifungal treatments.
May 2024 – Moberg Pharma AB announced that MOB-015 has obtained national marketing authorizations in all 13 European countries participating in the decentralized procedure. The local treatment is now authorized for use in adults with mild to moderate fungal nail infection (onychomycosis), broadening its availability across the European market.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 3.76 Billion |
| Market Size by 2032 | USD 5.40 Billion |
| CAGR | CAGR of 4.67% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Other Types) • By Treatment (Oral, Topical, Others) • By End Use (Hospitals, Dermatology Clinics, Homecare Settings, Ambulatory Surgical Centers) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bausch Health Companies, Pfizer, Novartis, Bayer, GlaxoSmithKline, Johnson & Johnson, Cipla, Moberg Pharma, Teva Pharmaceutical Industries, Galderma, and other players. |
Ans: The Onychomycosis Treatment Market is expected to grow at a CAGR of 4.67% from 2025 to 2032.
Ans: The Onychomycosis Treatment Market was USD 3.76 billion in 2024 and is expected to reach USD 5.40 billion by 2032.
Ans: An Increase in onychomycosis and fungal infections drives market growth.
Ans: The “Distal Subungual Onychomycosis” segment dominated the Onychomycosis Treatment Market.
Ans: North America dominated the Onychomycosis Treatment Market in 2024.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Onychomycosis (2024)
5.2 Prescription Trends (2024), by Region
5.3 Healthcare Spending on Onychomycosis Treatment (2024), by Region
5.4 Product Approval and Pipeline Analysis (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Onychomycosis Treatment Market Segmentation By Type
7.1 Chapter Overview
7.2 Distal Subungual Onychomycosis
7.2.1 Onychomycosis Treatment Market Trends Analysis (2021-2032)
7.2.2 Onychomycosis Treatment Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 White Superficial Onychomycosis
7.3.1 White Superficial Onychomycosis Market Trends Analysis (2021-2032)
7.3.2 White Superficial Onychomycosis Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Proximal Subungual Onychomycosis
7.4.1 Proximal Subungual Onychomycosis Market Trends Analysis (2021-2032)
7.4.2 Proximal Subungual Onychomycosis Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Other Types
7.5.1 Other Types Market Trends Analysis (2021-2032)
7.5.2 Other Types Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Onychomycosis Treatment Market Segmentation By Treatment
8.1 Chapter Overview
8.2 Topical
8.2.1 Topical Market Trend Analysis (2021-2032)
8.2.2 Topical Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Others
8.3.1 Other Market Trends Analysis (2021-2032)
8.3.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Oral
8.4.1 Oral Market Trends Analysis (2021-2032)
8.4.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Onychomycosis Treatment Market Segmentation By End Use
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2021-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Dermatology clinics
9.3.1 Dermatology clinics Market Trends Analysis (2021-2032)
9.3.2 Dermatology clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Homecare settings
9.4.1 Homecare settings Market Trends Analysis (2021-2032)
9.4.2 Homecare settings Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Ambulatory surgical centers
9.5.1 Ambulatory Surgical Centers Market Trends Analysis (2021-2032)
9.5.2 Ambulatory Surgical Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Onychomycosis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.4 North America Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.2.5 North America Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.6.2 USA Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.2.6.3 USA Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.7.2 Canada Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.2.7.3 Canada Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.8.2 Mexico Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.2.8.3 Mexico Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Onychomycosis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.4 Europe Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.5 Europe Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.6.2 Germany Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.6.3 Germany Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.7.2 France Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.7.3 France Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.8.2 UK Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.8.3 UK Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.9.2 Italy Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.9.3 Italy Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.10.2 Spain Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.10.3 Spain Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.11.2 Poland Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.11.3 Poland Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.12.2 Turkey Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.12.3 Turkey Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.4 Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.5 Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.6.2 China Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.6.3 China Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.7.2 India Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.7.3 India Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.8.2 Japan Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.8.3 Japan Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.9.2 South Korea Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.9.3 South Korea Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.10.2 Singapore Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.10.3 Singapore Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.11.2 Australia Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.11.3 Australia Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Onychomycosis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.6.2 UAE Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.5.6.3 UAE Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.8.2 Qatar Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.5.8.3 Qatar Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.9.2 South Africa Onychomycosis Treatment Market Estimates and Forecasts by Treatment (2021-2032) (USD Billion)
10.5.9.3 South Africa Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Onychomycosis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.4 Latin America Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.6.5 Latin America Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.6.2 Brazil Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.6.6.3 Brazil Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.7.2 Argentina Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.6.7.3 Argentina Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Onychomycosis Treatment Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Onychomycosis Treatment Market Estimates and Forecasts, by Treatment (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Onychomycosis Treatment Market Estimates and Forecasts, by End Use (2021-2032) (USD Billion)
11. Company Profiles
11.1 Bausch Health Companies
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Pfizer
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Novartis.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Bayer,
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 GlaxoSmithKline
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Johnson & Johnson,
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Cipla
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Moberg Pharma
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Teva Pharmaceutical Industries
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Galderma.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
By Treatment
By End Use
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/7612
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/7612
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report: